Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bb2121 Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
NCT03651128Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2019
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of idecabtagene vicleucel in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free Survival at 5 years. Started Apr 2019; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03651128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651128.